Literature DB >> 1615756

Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats.

B H Mitlak1, D C Williams, H U Bryant, D C Paul, R M Neer.   

Abstract

We examined the effect of intermittent administration of bovine parathyroid hormone (1-34) (bPTH) on spinal bone mineral content (BMC) and bone mineral density (BMD), serum 1,25-dihydroxyvitamin D concentrations, and serum markers of osteoblast function in senile male and female rats (23 and 24 months of age, respectively). Sexually mature young (3 month) male rats were similarly treated for comparison. bPTH administration increased serum osteocalcin concentrations without changing serum inorganic phosphate or calcium concentrations in either group of old animals. In young animals, PTH administration increased the serum calcium and inorganic phosphate concentrations significantly (p less than 0.05), although values remained within the normal range. In the vehicle-treated male rats, serum 1,25-dihydroxyvitamin D concentrations were lower in the senile than in the young animals (18 +/- 5 versus 47 +/- 6 pg/ml, p less than 0.05). PTH administration resulted in significantly increased serum 1,25-dihydroxyvitamin D concentrations in the senile and young male animals (both, p less than 0.05) and the final mean serum 1,25-dihydroxyvitamin D concentrations were not statistically different (68 +/- 9 versus 85 +/- 6 pg/ml respectively; p = NS). Serum 1,25-dihydroxyvitamin D concentrations were significantly (p less than 0.05) higher in the PTH-treated senile female rats than the sex-matched, vehicle-treated controls. The pretreatment spinal BMC and BMD as assessed by dual-energy x-ray absorptiometry (DEXA) were significantly higher in the senile male animals than in the young animals. Spinal BMC and BMD decreased in the vehicle-treated senile male rats (p less than 0.05) over the 3 weeks of the study despite a gain in weight.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615756     DOI: 10.1002/jbmr.5650070503

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  6 in total

1.  Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone.

Authors:  D Yang; R Singh; P Divieti; J Guo; M L Bouxsein; F R Bringhurst
Journal:  Bone       Date:  2007-02-16       Impact factor: 4.398

2.  Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats.

Authors:  V Shen; R Birchman; R Xu; M Otter; D Wu; R Lindsay; D W Dempster
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

3.  Effects of teriparatide retreatment in osteoporotic men and women.

Authors:  Joel S Finkelstein; Jason J Wyland; Benjamin Z Leder; Sherri-Ann M Burnett-Bowie; Hang Lee; Harald Jüppner; Robert M Neer
Journal:  J Clin Endocrinol Metab       Date:  2009-04-28       Impact factor: 5.958

4.  CBP/p300-interacting protein CITED1 modulates parathyroid hormone regulation of osteoblastic differentiation.

Authors:  Dehong Yang; Jun Guo; Paola Divieti; Toshi Shioda; F Richard Bringhurst
Journal:  Endocrinology       Date:  2008-01-10       Impact factor: 4.736

5.  Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol.

Authors:  V Shen; D W Dempster; R Birchman; R Xu; R Lindsay
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

6.  Serum 1,25-dihydroxyvitamin D: an outcome prognosticator in human sepsis.

Authors:  H Bryant Nguyen; Blen Eshete; K H William Lau; Adarsh Sai; Mark Villarin; David Baylink
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.